Human CD40 Ligand/TNFSF5 Antibody Summary
Leu50-Leu261
Accession # P29965
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
CD40 Ligand/TNFSF5 in Human Tonsil. CD40 Ligand/TNFSF5 was detected in immersion fixed paraffin-embedded sections of human tonsil using Mouse Anti-Human CD40 Ligand/TNFSF5 Monoclonal Antibody (Catalog # MAB617) at 15 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Mouse HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS002) and counterstained with hematoxylin (blue). Specific staining was localized to lymphocytes. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: CD40 Ligand/TNFSF5
CD40 Ligand (CD40L), now renamed TNFSF5 but also known as CD154, TRAP and gp39, is a 34‑39 kDa type II transmembrane glycoprotein that belongs to the TNF superfamily (1‑3). Human CD40L is 261 amino acids (aa) in length and consists of a 22 aa cytoplasmic domain, a 24 aa transmembrane segment, and a 215 aa extracellular region that consists of multiple beta -strands and one N‑linked glycosylation site (4, 5). Although carbohydrates are present, they are not necessary for activity (6). As with other TNF superfamily members, CD40L will exist as a trimer, both as a membrane bound and soluble form (6‑8). The soluble form is 18 kDa in size and about 150 aa in length, and arises from intracellular proteolytic processing. As a trimer, the soluble form is bioactive (7‑9). Multiple mutations and alternate splice forms of CD40L exist, often associated with pathology and leading to truncated or nontrimerizable forms of CD40L (8). While CD40L is a ligand for CD40, the ligation of CD40L by CD40 initiates bidirectional signaling in both CD40 and CD40L expressing cells (10). The extracellular region of human CD40L is 99%, 88%, 86%, 82%, 75% and 75% aa identical to the extracellular regions of CD40L in rhesus monkey, bovine, porcine, canine, mouse and rat, respectively. CD40L binds to both CD40 and to integrin alpha IIb beta 3 (CD41) (3, 11). In the cell membrane, it also associates with a unique splice variant of CD28 (CD28i) that may facilitate CD40L signal transduction (12). CD40L is expressed by monocytes, NK cells, mast cells, basophils, smooth muscle cells, endothelial cells, dendritic cells, activated and resting B cells, plus activated platelets and CD4+ T cells (13, 14). CD40L ligation of CD40 on dendritic cells (DC) initiates DC maturation and differentiation. CD40L signaling into naïve B cells promotes germinal center formation and isotope switching. With IL-21, CD40L generates IgA plus IgG3; with IL-4, CD40L generates IgG1 secretion (14, 15).
- Zhang, G. (2004) Curr. Opin. Struct. Biol. 14:154.
- Hehlgans, T. and K. Pfeffer (2005) Immunology 115:1.
- Quezada, S.A. et al. (2004) Annu. Rev. Immunol. 22:307.
- Graf, D. et al. (1992) Eur. J. Immunol. 22:3191.
- Hollenbaugh, D. et al. (1992) EMBO J. 11:4313.
- Khandekar, S.S. et al. (2001) Prot. Exp. Purif. 23:301.
- Pietravalle, F. et al. (1996) J. Biol. Chem. 271:5965.
- Garber, E. et al. (1999) J. Biol. Chem. 274:33545.
- Vakkalanka, R.K. et al. (1999) Arthritis Rheum. 42:871.
- Eissner, G. et al. (2004) Cytokine Growth Factor Rev. 15:353.
- Prasad, K.S. et al. (2003) Proc. Natl. Acad. Sci. USA 100:12367.
- Mikolajczak, S.A. et al. (2004) J. Exp. Med. 199:1025.
- Lievens, D. et al. (2009) Thromb. Haemost. 102:206.
- Elgueta, R. et al. (2009) Immunol. Rev. 229:152.
- Avery, D.T. et al. (2008) J. Immunol. 181:1767.
Product Datasheets
Citations for Human CD40 Ligand/TNFSF5 Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
7
Citations: Showing 1 - 7
Filter your results:
Filter by:
-
Ex vivo-expanded human CD19+TIM-1+ regulatory B cells suppress immune responses in vivo and are dependent upon the TIM-1/STAT3 axis
Authors: S Shankar, J Stolp, SC Juvet, J Beckett, PS Macklin, F Issa, J Hester, KJ Wood
Nature Communications, 2022-06-03;13(1):3121.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization -
Novel genetic features of human and mouse Purkinje cell differentiation defined by comparative transcriptomics
Authors: DE Buchholz, TS Carroll, A Kocabas, X Zhu, H Behesti, PL Faust, L Stalbow, Y Fang, ME Hatten
Proc. Natl. Acad. Sci. U.S.A., 2020-06-16;117(26):15085-15095.
Species: Human
Sample Types: Whole Tissue
Applications: IHC -
CD40-targeting KGYY15 peptides do not efficiently block the CD40–CD40L interaction
Authors: Damir Bojadzic, Peter Buchwald
Diabetologia
-
Design, Synthesis, and Evaluation of Novel Immunomodulatory Small Molecules Targeting the CD40?CD154 Costimulatory Protein-Protein Interaction
Authors: D Bojadzic, J Chen, O Alcazar, P Buchwald
Molecules, 2018-05-11;23(5):.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Up-Regulated Expression of Matrix Metalloproteinases in Endothelial Cells Mediates Platelet Microvesicle-Induced Angiogenesis
Authors: C Sun, SB Feng, ZW Cao, JJ Bei, Q Chen, WB Zhao, XJ Xu, Z Zhou, ZP Yu, HY Hu
Cell. Physiol. Biochem., 2017-04-27;41(6):2319-2332.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization -
Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement.
Authors: Maniar A, Zhang X, Lin W, Gastman BR, Pauza CD, Strome SE, Chapoval AI
Blood, 2010-06-02;116(10):1726-33.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization -
Distinct subsets of human invariant NKT cells differentially regulate T helper responses via dendritic cells.
Authors: Liu TY, Uemura Y, Suzuki M, Narita Y, Hirata S, Ohyama H, Ishihara O, Matsushita S
Eur. J. Immunol., 2008-04-01;38(4):1012-23.
Species: Human
Sample Types: Whole Cells
Applications: Blocking
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human CD40 Ligand/TNFSF5 Antibody
Average Rating: 3 (Based on 1 Review)
Have you used Human CD40 Ligand/TNFSF5 Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by: